• 
• 
• 
• 
• 
  • Overview
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
    • Key Ratios
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
    • Insider Ownership
  • Contact Us
  
  • Shareholder Briefcase
  • Printed Materials
  • Email Alerts
  • Download Library
  • RSS Feeds
• 
• 
• 

Print page     Email page

Management

show all hide all

Craig A. Wheeler

President and Chief Executive Officer

Mr. Wheeler was previously President of Chiron BioPharmaceuticals, the biotechnology division of Chiron Corporation, which manufactured and distributed products treating cancer, cystic fibrosis, and multiple sclerosis. During his tenure, global sales in the division doubled to over $600 million, five new programs were put into clinical development, and a new product was launched. Prior to joining Chiron, Mr. Wheeler served as a partner at The Boston Consulting Group in the firm's healthcare practice.

Jo-Ann Beltramello

Vice President, Human Resources

John E. Bishop Ph.D.

Senior Vice President, Pharmaceutical Sciences

Dr. Bishop was previously at Millennium Pharmaceuticals where he was most recently responsible for chemical and biologic process development, managing Millennium's process development group and leading manufacturing efforts for many of Millennium's small-molecule and biologic clinical candidates. Prior to joining Millennium, Dr. Bishop was involved in leading process development efforts on several projects at DuPont Merck Pharmaceuticals.

Steven B. Brugger

Chief Operating Officer

Mr. Brugger was previously Vice President at Millennium Pharmaceuticals where he was responsible for building strategic marketing, project and portfolio management capabilities, leading the inflammation and metabolic franchises, and managing multiple pharmaceutical collaborations. Prior to joining Millennium, Mr. Brugger spent 19 years in the pharmaceutical industry, holding positions in product development and marketing at Hoechst, Ayerst and Novartis. His most recent position before joining Millennium was as head of marketing for Novartis' Transplantation, Tissue Engineering and Immunology business unit in the U.S.

Ian Fier

Vice President, Development Operations

Mr. Fier was previously Vice President of Clinical Affairs at BioTransplant Incorporated, where he was responsible for building the clinical development organization, formulating product strategy and directing product development activities for both antibody-based therapeutics and medical devices. Prior to joining BioTransplant, he held positions in product development and program management at The Medicines Company and Astra USA where his responsibilities included the clinical development of several currently marketed products in the cardiovascular, pulmonary, gastrointestinal and internal medicine fields.

Catharine Johnson, Ph.D.

Vice President, Corporate Development

Dr. Johnson joined Momenta in 2005. Previously, Dr. Johnson served as a Principal at Atlas Venture in the life sciences sector. In this role she was responsible for identifying and negotiating investments in new life sciences companies, and also served as an advisor to existing biotech portfolio companies. Dr. Johnson was also head of business development at Regeneron Pharmaceuticals, where she was responsible for new business initiatives, strategic partnering, and alliance management. Dr. Johnson received her Doctorate from the Johns Hopkins School of Medicine's department of Biological Chemistry.

Kei Kishimoto, Ph.D.

Vice President, Biology

Gerard E. (Rod) Riedel Ph.D.

Vice President, Regulatory Affairs

Dr. Riedel was previously Senior Vice President of Regulatory Affairs, Quality Assurance and Project Management at PRAECIS Pharmaceuticals, Inc. In addition to his departmental responsibilities, Dr. Riedel also chaired PRAECIS' Management Review Committee, which supervised all R&D activities within the company. Prior to joining PRAECIS, he held senior positions in R&D Project Management at Wyeth Research and Genetics Institute, Inc.

Jim Roach, M.D

Chief Medical Officer

Jim Roach, M.D. brings extensive product development and commercialization experience to Momenta as Chief Medical Officer. Prior to joining Momenta, Dr. Roach was the Senior Vice President of Medical Affairs at Sepracor. He has also held senior clinical research and/or medical affairs positions at Millennium Pharmaceuticals, LeukoSite, Medical and Technical Research Associates, and Astra USA. Dr. Roach is Board Certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine. He has been affiliated with the Pulmonary and Critical Care Medicine Division of Brigham and Women's Hospital since 1993 and is an Assistant Clinical Professor of Medicine at Harvard Medical School. Dr. Roach is also a Fellow of the American College of Physicians and the American College of Chest Physicians. He received his BA majoring in Biology and Philosophy from the College of the Holy Cross, and his medical degree from Georgetown University School of Medicine.

Barbara Rosengren

Vice President, Strategic Product Development

Ms. Rosengren was previously Vice President and Development Project Leader at Millennium Pharmaceuticals where she led the project management activities for the Inflammation franchise, including co-development activities with key Millennium partners. Ms. Rosengren also serves as a guest faculty instructor in the Project Management courses at Massachusetts Biotechnology Council and the Harvard Extension School. Prior to joining Millennium, Ms. Rosengren held a variety of commercial and project management positions at Sandoz and subsequently Novartis Pharmaceuticals for both the global and U.S. business units.

Richard P. Shea

Chief Financial Officer

Mr. Shea was previously Chief Operating Officer, CFO and Treasurer at Variagenics, Inc., a pharmacogenomics company, where he assisted in raising over $120 million, including a successful IPO. While at Variagenics, Mr. Shea was responsible for Finance, Legal, Investor Relations, Human Resources and Operations. Prior to this, Mr. Shea was Vice President of Finance at Genetics Institute, Inc. (now Wyeth), and a Senior Manager at PricewaterhouseCoopers.

Ganesh Venkataraman Ph.D.

Senior Vice President, Chief Scientific Officer

Dr. Venkataraman is one of Momenta's scientific founders. Prior to founding Momenta, Dr. Venkataraman was a member of the MIT faculty where he pioneered research in the area of analytical techniques for complex carbohydrates. He also served as the Director of Bioinformatics for the Consortium for Functional Glycomics, a multi-million-dollar NIH initiative to study the role of complex sugars in biology.